Midday Report: NovoCure (NVCR) Falls on October 24

Today, NovoCure Ltd (NASDAQ:NVCR) is down 11.45%.

The last price as of 12:04:21 was $63.68. NovoCure fell $8.31 from the previous day’s close.

498,082 shares were traded today.

Since the last close, NovoCure is up 3.29% year-to-date. The company expects its next earnings on 10/27/2022.

For NovoCure technical charts, analysis and more, visit the company profile.

About NovoCure Ltd

Novocure is a global oncology company working to extend survival for some of the most aggressive types of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating tumor treatment areas in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

For more information about NovoCure Ltd and to follow the latest company updates, you can visit the company’s profile page here: NovoCure Ltd Profile. For more financial market news, visit Equities News. Also, don’t forget to subscribe to the Equities News Fix to get the best breaking news in your inbox.

Sources: The symbol info widget is provided by TradingView based on 15 minute lagged prices. All other item data is provided by IEX Cloud at 15-minute delayed prices or EOD company information.

Stock price data is provided by IEX Cloud with a 15 minute delay. Chart price data is provided by TradingView with a 15 minute delay.

The views and opinions expressed in this article are those of the authors and do not represent the views of equities.com. Readers should not take statements by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

The biotech sector heats up in the news about treating Alzheimer’s

Military spending will support defense stocks

Central bank digital currencies may be inevitable, and that’s a problem

Jeff Kagan: AT&T’s Future Looks… Bright?

Even in a recession, vacation travel is a top priority

Big Pharma and the need for speed

Pondering Meta’s Next Move As Confidence Crisis Grows: Jeff Kagan

Where are the stock market leaders?